Abstract: The literature of QT interval prolongation caused by antiviral drugs of clinical regimens or clinical trial protocols in Corona Virus Disease 2019(COVID-2019) patients was reviewed. According to the results of literature review, lopinavir/ritonavir and chloroquine have the potential risk of drug-induced long QT syndrome. In COVID-2019 patients, medication risk of drug-induced long QT syndrome should be concerned. The clinician and pharmacists should be familiar with the type of drugs that can cause QT interval prolongation, improve the ability to identify the factors of QT interval prolongation and drug interactions in patients, pay attention to ECG monitoring and electrolyte management to prevent clinical potential drug induced acute arrhythmia events and reduce adverse drug events in COVID-2019 patients.